Applicability of recently established reference values for serum insulin-like growth factor 1: A comparison of two assays - An (automated) chemiluminescence immunoassay and an enzyme-linked immunosorbent assay

Clinical Laboratory

Volumn 51, Issue 7-8, 2005, Pages 381-387

  Ivan, Diana ^a   Brabant, Georg ^b   Kann, Peter H ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemiluminescense assay; Enzyme linked immunosorbent assay; IGF 1; Reference values

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOANALYSIS; CHEMOLUMINESCENCE; CHILD; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PROTEIN DETERMINATION; REFERENCE VALUE;

ADOLESCENT; ADULT; AGED; CHEMILUMINESCENT MEASUREMENTS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; INFANT; INSULIN-LIKE GROWTH FACTOR I; MALE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 23844502086     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83: 379-81.
2. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research So-ciety. J Clin Endocrinol Metab 2000; 85: 3990-3.
3. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999; 84: 2013-9.
4. Peacey SR, Shalet SM. Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly. Ann Clin Biochem 2001; 38: 297-303.
5. Leung KC, Ho KK. Measurement of growth hormone, insulin-like growth factor I and their binding proteins: the clinical aspects. Clin Chim Acta 2001; 313: 119-23.
6. Brabant G. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol 2003; 148: S15-20.
7. Lee PD, Rosenfeld RG. Clinical utility of insulin-like growth factor assays. Pediatrician 1987; 14: 154-61.
8. Drake WM, Howell SJ, Monson JP, Shalet SM. Optimizing gh therapy in adults and children. Endocr Rev 2001; 22: 425-50.
9. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6.
10. Burroughs KD, Dunn SE, Barrett JC, Taylor JA. Insulin-like growth factor-I: a key regulator of human cancer risk? J Natl Cancer Inst 1999; 91: 579-81.
11. Brabant G, von zur Mühlen A, Wüster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003; 60: 53-60.